Breast cancer patients likely to skip follow-up therapy if not treating other chronic ills

June 09, 2016

Researchers at Columbia University's Mailman School of Public Health and Columbia University Medical Center, and NewYork-Presbyterian, found that patients who did not adhere to their medication schedule for chronic conditions, such as hypertension, diabetes, and thyroid disease, prior to a breast cancer diagnosis were twice as likely to skip oral adjuvant hormonal therapy. Patients who skipped medications for their chronic conditions had a 23 percent non-adherence rate to hormone treatment, compared with 10 percent for those who took one or more drugs for their conditions prior to a breast cancer diagnosis.

The study is among the first to associate prior medication adherence patterns and subsequent adherence for breast cancer drug therapy. Findings are published online in JAMA Oncology.

This large population-based study was based on data from the Truven Health Analytics MarketScan, a medical and pharmacy insurance claims database. The researchers identified 21,255 women 18 years or older who were diagnosed with breast cancer in 2010-2012 and had filled two or more prescriptions for tamoxifen and/or an aromatase inhibitor. Overall, 16 percent were non-adherent to their hormone replacement therapy.

"Given the fact that medications used in oncology are potentially life-saving or life-prolonging, it is surprising that non-adherence to these medications is common," said Alfred I. Neugut, MD, PhD, Myron M. Studner Professor of Cancer Research and Professor of Epidemiology at Columbia University's Mailman School of Public Health and lead author of the study.

Age had a strong association with adherence versus non-adherence. Compared to women with breast cancer between the ages of 55 and 64, women younger than 45 years and those between the ages of 45 to 54 were more likely to be less adherent, as were those 75 years of age or older. Women who were African-American, being treated by a specialist other than a medical oncologist, as well as those who had poor belief in the treatment's efficacy, lower financial resources, and higher co-payments for the drug, were also less likely to adhere to the treatment. As the 30-day out-of-pocket costs rose from $5, there was a gradual increase in non-adherence.

Having a greater number of chronic conditions and a history of non-adherence to chronic medications in the year prior to a patient's breast cancer diagnosis--regardless of the number of medications a woman was taking--was also associated with not taking the medications. "This finding revealed that those who are non-adherent to chronic medications are at increased risk for non-adherence to hormone therapy and could benefit from vigilance and possible future interventions," noted Dr. Neugut.

Of the women studied, 62 percent initially used aromatase inhibitors, while 38 percent started with tamoxifen. Almost two-thirds (63 percent) used at least one prior medication for a chronic condition. These included common drugs for six chronic conditions: diabetes, hypertension, hyperlipidemia, thyroid disease, osteoporosis, and gastroesophageal reflux disease (GERD). The average rates of non-adherence in the year prior to the hormone therapy were substantial: 37 percent for diabetes; 28 percent, hypertension; 30 percent, hyperlipidemia; 21 percent, thyroid disease; 32 percent, osteoporosis; and 38 percent, gastroesophageal reflux disease.

"Non-adherence to hormone therapy for breast cancer can have significant impact on survival outcomes," said Dr. Neugut, who is also co-director of the Cancer Prevention Program at NewYork-Presbyterian. "The hope is that by identifying patients at highest risk for non-adherence and having a detailed history of medication use, interventions can be developed and targeted at higher- risk groups."
Co-authors: Xiaobo Zhong, MS; Jason D. Wright, MD; Melissa Accordino, MD; Jingyan Yang, MHS; and Dawn L. Hershman, MD, MS.

The study was supported by the Department of Defense (grant BC043120), the American Medical Association, Breast Cancer Research Foundation, the American Society of Clinical Oncology, and the Witten Family Foundation. Dr. Neugut has served as a consultant to Pfizer, Teva Pharmaceuticals, Takeda Pharmaceuticals, United BioSource Corporation and serves on the Medical Advisory Board of EHE, Intl. No financial conflicts are reported.

About Columbia University's Mailman School of Public Health

Founded in 1922, Columbia University's Mailman School of Public Health pursues an agenda of research, education, and service to address the critical and complex public health issues affecting New Yorkers, the nation and the world. The Mailman School is the third largest recipient of NIH grants among schools of public health. Its over 450 multi-disciplinary faculty members work in more than 100 countries around the world, addressing such issues as preventing infectious and chronic diseases, environmental health, maternal and child health, health policy, climate change & health, and public health preparedness. It is a leader in public health education with over 1,300 graduate students from more than 40 nations pursuing a variety of master's and doctoral degree programs. The Mailman School is also home to numerous world-renowned research centers including ICAP (formerly the International Center for AIDS Care and Treatment Programs) and the Center for Infection and Immunity. For more information, please visit

Columbia University Medical Center provides international leadership in basic, preclinical, and clinical research; medical and health sciences education; and patient care. The medical center trains future leaders and includes the dedicated work of many physicians, scientists, public health professionals, dentists, and nurses at the College of Physicians and Surgeons, the Mailman School of Public Health, the College of Dental Medicine, the School of Nursing, the biomedical departments of the Graduate School of Arts and Sciences, and allied research centers and institutions. Columbia University Medical Center is home to the largest medical research enterprise in New York City and State and one of the largest faculty medical practices in the Northeast. For more information, visit or

About NewYork-Presbyterian

NewYork-Presbyterian is one of the nation's most comprehensive healthcare delivery networks, focused on providing innovative and compassionate care to patients in the New York metropolitan area and throughout the globe. In collaboration with two renowned medical school partners, Weill Cornell Medicine and Columbia University College of Physicians & Surgeons, NewYork-Presbyterian is consistently recognized as a leader in medical education, groundbreaking research and clinical innovation. For more information, visit

Columbia University's Mailman School of Public Health

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to